Ikaria, Inc. - Now A Part Of Mallinckrodt Pharmaceuticals. company information, Employees & Contact Information

Mallinckrodt plc to Report Third Quarter 2025 Financial Results on November 10, 2025 Lelezard

Mallinckrodt plc to Report Fourth Quarter and Fiscal Year 2024 Financial Results PR Newswire

Mallinckrodt Finalizes Settlement to Resolve "Track 1" Opioid Cases with the Ohio Counties of Cuyahoga and Summit PR Newswire

Mallinckrodt Announces Board of Directors and Leadership Updates PR Newswire

Mallinckrodt Receives Necessary Ruling from Irish High Court to Combine with Endo, Inc. PR Newswire

Mallinckrodt Agrees to Sell BioVectra Inc. to H.I.G. Capital for $250 Million PR Newswire

Mallinckrodt Receives Approval to List on NYSE American PR Newswire

Mallinckrodt plc Reports Third Quarter 2024 Financial Results and Raises Full Year Guidance PR Newswire

Mallinckrodt plc Reports First Quarter 2025 Financial Results and Reaffirms Full-Year Guidance PR Newswire

Mallinckrodt plc Reports First Quarter 2024 Financial Results and Reaffirms Full Year Guidance PR Newswire

Mallinckrodt Reaches Agreement to Sell Therakos® Business to CVC for $925 Million PR Newswire

Mallinckrodt Gains Support for Its Restructuring Support Agreement from Lenders Holding Approximately $1.3 Billion of Its First Lien Term Loans PR Newswire

Mallinckrodt, Endo Announce Planned Leadership Team for Merged Company PR Newswire

Mallinckrodt Completes Financial Restructuring and Irish Examinership Proceedings and Emerges From Chapter 11 PR Newswire

Mallinckrodt To Present At Wells Fargo Securities Healthcare Conference PR Newswire

Mallinckrodt and Endo Announce Significant Progress in Proposed Merger PR Newswire

Mallinckrodt Completes Divestiture of Therakos® Business PR Newswire

Mallinckrodt plc Provides Update on Executive Committee PR Newswire

Mallinckrodt Opens Specialty Brands Office In New Jersey, Announces $100,000 Donation To Princeton University Program For High Achieving, Low-Income High School Students PR Newswire

Mallinckrodt Plans Spin-Off of Specialty Generics Business to Shareholders PR Newswire

Mallinckrodt Enters Agreement To Sell Its Nuclear Imaging Business To IBA Molecular For Approximately $690 Million PR Newswire

Mallinckrodt Locates Growing Specialty Brands Businesses In Bedminster, N.J.; Continues Significant St. Louis Reinvestment PR Newswire

Mallinckrodt's Hobart, N.Y. Site Recognized With Two Manufacturing Leadership Awards PR Newswire

Mallinckrodt Completes Sale Of Its Nuclear Imaging Business To IBA Molecular For Approximately $690 Million PR Newswire

Mallinckrodt Completes Acquisition Of Sucampo Pharmaceuticals, Inc. PR Newswire

Mallinckrodt Completes Acquisition Of Stratatech Corporation, A Regenerative Medicine Company Focused On Proprietary Therapeutic Human Skin Substitute Products PR Newswire

Mallinckrodt To Sell Intrathecal Therapy Business To Piramal Enterprises Limited For Approximately $203 Million PR Newswire

Mallinckrodt Completes Acquisition of InfaCare Pharmaceutical Corporation and Stannsoporfin, its Proprietary Therapy in Late-Stage Development for Newborns at Risk for Severe Jaundice PR Newswire

Mallinckrodt And Silence Therapeutics Announce Collaboration To Develop And Commercialize RNAi Therapeutics For Complement-Mediated Diseases PR Newswire

Mallinckrodt Completes Sale Of Its Intrathecal Therapy Business To Piramal Enterprises Limited For Approximately $203 Million PR Newswire

Mallinckrodt Completes Acquisition of Ocera Therapeutics and OCR-002, Its Proprietary Therapy in Development for Treatment of Hepatic Encephalopathy PR Newswire

Mallinckrodt And Federal Trade Commission Resolve Questcor Matter PR Newswire

Mallinckrodt Pharmaceuticals distributes more than 2K gallons of hand sanitizer to Missouri The Missouri Times

Mallinckrodt To Acquire Ocera Therapeutics And OCR-002, Its Proprietary Therapy In Development For Treatment Of Hepatic Encephalopathy PR Newswire

Mallinckrodt Builds Leadership To Support Continued Growth PR Newswire

Mallinckrodt and Endo to Merge citybiz

Mallinckrodt Completes Expansion of Operations and Manufacturing Facility for StrataGraft® Regenerative Skin Tissue in Madison, Wis. PR Newswire

Mallinckrodt's SpecGx LLC Reports on Outcome of FDA Joint Advisory Committee on Abuse-Deterrent, Immediate-Release Reformulation of Roxicodone® (Oxycodone Hydrochloride) PR Newswire

Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million PR Newswire

Mallinckrodt and Endo Merger Update citybiz

Mallinckrodt Announces UVADEX® (Methoxsalen) Approved in Australia for use with the THERAKOS® CELLEX® Photopheresis System for Treatment of Chronic Graft Versus Host Disease (cGvHD) and Skin Manifestations of Cutaneous T-Cell Lymphoma (C PR Newswire

Mallinckrodt Earns International Standard ISO 13485:2016 and Medical Device Single Audit Program (MDSAP) Certifications for INOmax® DSIR® Plus Nitric Oxide Delivery Systems PR Newswire

Mallinckrodt's SpecGx LLC Receives FDA Complete Response Letter for Abuse-Deterrent, Immediate-Release Reformulation of Roxicodone® (Oxycodone Hydrochloride) PR Newswire

Mallinckrodt To Acquire InfaCare Pharmaceutical Corporation And Stannsoporfin, Its Proprietary Therapy In Late-Stage Development For Treatment Of Newborns At Risk For Developing Severe Jaundice PR Newswire

Mallinckrodt Supports Investigator-Initiated Study at Massachusetts General Hospital to Assess Effectiveness of Inhaled Nitric Oxide in Patients with Severe Acute Respiratory Distress Syndrome Due to COVID-19 PR Newswire

Mallinckrodt To Acquire Stratatech Corporation, A Regenerative Medicine Company Focused On Proprietary Therapeutic Human Skin Substitute Products PR Newswire

Ventilators respiratory-therapy.com

IBA Molecular Acquires Mallinckrodt Nuclear Imaging Imaging Technology News

Mallinckrodt Announces Donation of Two Transport Vehicles to Coolmine Therapeutic Community (TC) PR Newswire UK